New alert for weight loss drug users

The study indicates that the benefits of weight-loss medications from the GLP-1 class, such as Ozempic, Wegovy, and Mounjaro, which help improve heart health and reduce the risks of cardiovascular diseases, begin to decline after discontinuation. The results showed that individuals who continued treatment had an 18% lower risk of heart attacks, strokes, and mortality, while this risk increased by 14% after one year of stopping and reached 22% after two years. Experts emphasize the importance of not stopping these medications abruptly without medical consultation, as discontinuation can lead to weight regain and other health issues such as blood pressure, cholesterol, and heart inflammations. It is essential to follow a well-planned treatment regimen with a doctor to ensure ongoing health benefits and minimize risks.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل